On Monday, Shares of Trinity Industries Inc. (NYSE:TRN), dropped -1.99% to $28.13.
Trinity Industries, declared earnings results for the first quarter ended March 31, 2015, counting the following noteworthy highlights:
- First quarter earnings per common diluted share of $1.13 contrast to $1.42 for the first quarter of 2014
- Earnings in the first quarter comprised of $0.18 per common diluted share related to sales of leased railcars contrast to $0.75 per share in the same quarter last year
- Rail, Inland Barge, and Energy Equipment Groups stated higher year-over-year operating profit during the first quarter
- Rail Group delivered a record 8,710 railcars and received orders for 4,865 new railcars during the first quarter resulting in a backlog of 57,190 units with a value of $6.81 billion
- Inland Barge Group received orders of $280.6 million, elevating backlog to $565.4 million, its highest level in over six years
- Company raised earnings guidance for full year 2015 to between $4.10 and $4.45 per common diluted share contrast to previous guidance of between $4.00 and $4.40 per share.
Trinity Industries, Inc. provides various products and services for the energy, transportation, chemical, and construction sectors in the United States and internationally. Its Rail Group segment offers railcars, counting autorack, box, covered hopper, gondola, intermodal, tank, and open hopper cars; and couplers, axles, and other equipment, in addition to railcar maintenance services.
Shares of Boston Scientific Corporation (NYSE:BSX), declined -1.96% to $17.98, during its last trading session, hitting its highest level.
Boston Scientific, is planned to take part in the Bank of America Merrill Lynch 2015 Healthcare Conference on May 12 in Las Vegas.
Dan Brennan, executive vice president and chief financial officer, and Susie Lisa, vice president, Investor Relations, will take part in a 30-minute question and answer session regarding the company with the host analyst at about 10 a.m. PT.
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in three segments: Cardiovascular, Rhythm Administration, and MedSurg.
At the end of Monday’s trade, Shares of The Wendy’s Company (NASDAQ:WEN), dwindled -1.96% to $10.50.
The Wendy’s Company, declared the appointment of Kurt Kane, 43, to the newly created position of Chief Concept Officer, responsible for all North America Marketing and Innovation efforts for the Wendy’s® brand, effective May 4. Kane will report to President and CEO Emil Brolick and serve as a member of the Senior Leadership Team.
Most recently, Kane served as Global Chief Marketing and Food Innovation Officer at Pizza Hut, Inc. In this role, he was responsible for the development of the planned direction for Pizza Hut, in addition to the execution of advertising, media planning, and product innovation across 13,600 restaurants in 87 countries. Kane started his tenure with Pizza Hut in 2008 as VP of Marketing, and held roles of increasing responsibility, counting VP of National Marketing and Communications, and U.S. Chief Marketing Officer.
Kane began his career as an air defense artillery officer with the U.S. Army’s 4th Infantry Division, after graduating with a B.S. in Administration from the United States Military Academy at West Point. He received an MBA from the University of Texas at Austin.
The Wendy’s Company, through its auxiliaries, owns and franchises Wendy’s restaurant system. The company is involved in operating, developing, and franchising a system of quick-service restaurants. As of December 28, 2014, its restaurant system comprised of 6,515 restaurants, of which about 957 were company-operated restaurants in the United States and 27 foreign countries.
Finally, Nektar Therapeutics (NASDAQ:NKTR), ended its last trade with -1.95% loss, and closed at $10.56.
Nektar Therapeutics, will declare its financial results for the first quarter ended March 31, 2015 on Thursday, April 30, 2015, after the close of U.S.-based financial markets. Howard Robin, president and chief executive officer, will host a conference call to review the results starting at 5:00 p.m. Eastern Time (ET)/2:00 p.m. Pacific Time (PT).
Nektar Therapeutics, a biopharmaceutical company, develops drug candidates that utilize its PEGylation and polymer conjugate technology platforms in the United States. Its product pipeline comprises drug candidates in therapeutic areas comprising oncology, pain, anti-infectives, and immunology.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
